CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]
CAMBRIDGE, Mass., January 31, 2023 – Casma Therapeutics, a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., has stepped down as Chief Executive Officer, effective January 13, 2023. Dr. Dionne will continue to serve on the Board of Directors. Frank Gentile, Ph.D., formerly Chief Operating Officer […]
In their recent Nature paper, Casma Founders Jim Hurley and Andrea Ballabio describe the cryogenic-EM structure of an MTORC1 megacomplex. A molecular description of this massive complex is helping us understand the regulation of the TFEB transcription factor and dependence of TFEB phosphorylation on FLCN and the RagC GDP state. Read full publication here
CAMBRIDGE, Mass., November 15, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million. New investors participating in the round include Amgen Ventures, LLC, Astellas Venture Management, Eisai Co., Ltd., Euclidean Capital, Mirae Asset, and Ono […]
CAMBRIDGE, Mass., November 8, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the Stifel 2022 Healthcare Conference on Wednesday November 16,, 2022 at 3:00pm ET in New York, NY. About Casma Therapeutics, Inc. Casma […]
CAMBRIDGE, Mass., May 17, 2022 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer, will present at the UBS 2022 Global Healthcare Conference on Tuesday, May 24, 2022 at 11:30 a.m. ET in New York, NY. About Casma Therapeutics […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Casma Therapeutics, Inc., today announced the appointment of two executives with extensive experience in drug discovery and translational medicine to further the company’s goal of leveraging the natural cellular process of autophagy to treat neurodegenerative, inflammatory and lysosomal storage disorders, among other conditions. Jeffrey Saunders, Ph.D., Casma’s new senior vice president of drug […]
CAMBRIDGE, Mass., September 11, 2018 — Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced a research collaboration with Fondazione Telethon, founder of the Telethon Institute of Genetics and Medicine (TIGEM), to develop new therapies for lysosomal storage disorders and more common disorders such as neurodegeneration. TIGEM, an international research […]
CAMBRIDGE, Mass., Dec. 6, 2018 – Casma Therapeutics, Inc. today announced an exclusive and nonexclusive license to technology developed at The University of Texas Southwestern Medical Center that will advance the company’s drive to harness the natural cellular processes of autophagy to design powerful new medicines for a broad range of diseases.The license includes commercial rights to a […]
CAMBRIDGE, Mass. – Dec. 12, 2018 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointment of two senior executives who will help lead Casma through its next phase of growth. Caren Block, Casma’s new vice president of people & culture, has extensive experience in […]
CAMBRIDGE, Mass. – March 26, 2019 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced the appointments of Sascha Martens, Ph.D., and Pietro De Camilli, M.D., as the first members of Casma’s scientific advisory board. Martens, an expert in autophagy research, is currently professor and head […]